GLAND

GLAND PHARMA LIMITED

August 10, 2026

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
25th floor, Dalal Street
Mumbai - 400 001
Scrip Code: 543245

National Stock Exchange of India Limited
Listing Department
Exchange Plaza, 5th floor
Plot no. C-1, Block G, Bandra Kurla Complex Bandra (East), Mumbai - 400 051
Symbol: GLAND (ISIN: INE068V01023)

Dear Sir/Madam,

Sub: Outcome of the Board Meeting

In continuation to our intimation dated July 24, 2026, regarding the Board Meeting Notice, we would like to inform you that the Board of Directors (the "**Board**") of Gland Pharma Limited (the "**Company**") at its Meeting held today, i.e. **Monday, August 10, 2026,** has *inter-alia* considered and approved the Unaudited Financial Results (standalone and consolidated) along with the Limited Review Report(s) for the quarter ended June 30, 2026, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations') which has been duly reviewed and recommended by the Audit Committee.

In this regard, please find enclosed copies of the:

1. Unaudited Financial Results (standalone and consolidated) along with Limited Review Report(s) of the Company for the quarter ended June 30, 2026 prepared in compliance with Indian Accounting Standards (Ind AS)

2. Press Release and Investor Presentation on the financial results of the Company for the above period.

The Board Meeting commenced at 15.00 Hrs. IST and ended at 16.05 Hrs. IST.

This is for your information and records.

Yours truly,
For Gland Pharma Limited

Pallerlamudi Sampath Kumar

Digitally signed by Pallerlamudi Sampath Kumar
DN: cn=Pallerlamudi Sampath Kumar, c=IN, o=Personal, email=sampath@glandpharma.com
Date: 2026.08.10 16:09:41 +05'30'

Sampath Kumar Pallerlamudi
Company Secretary & Compliance Officer

Encl: As above

Deloitte Haskins & Sells

Chartered Accountants
Meenakshi Pride Rock-Tower III
[Block-M], 8th & 9th Floors,
Survey No. 23, Gachibowli,
Serilingampally Municipality
Ranga Reddy District,
Hyderabad-500032
Telangana, India

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF
GLAND PHARMA LIMITED

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **Gland Pharma Limited** ("the Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group"), for the quarter ended June 30, 2026 ("the Statement") being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Holding Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:

Srl. No.	Name of the entity	Relationship
1	Gland Pharma Limited	Holding Company
2	Gland Pharma International Pte. Ltd., Singapore	Wholly-owned subsidiary
	Subsidiaries of Gland Pharma International Pte. Ltd.:	
3	Gland Pharma USA Inc., USA	Wholly-owned subsidiaries
4	Phixen SAS, France	
	Subsidiaries of Phixen SAS:	
5	Cenexi SAS, France	Wholly-owned subsidiaries
6	Cenexi HSC SAS, France	
7	Cenexi Laboratories Thissen SA, Belgium	
8	Phineximmo SA, Belgium	
9	Gland Pharma Europe SAS, France	

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review report of the other auditor referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the interim financial information of two subsidiaries included in the consolidated unaudited financial results, whose financial information reflects total revenues of ₹ 1,654.54 million, total profit after tax of ₹ 82.44 million and total comprehensive income of ₹ 82.44 million for the quarter ended June 30, 2026, as considered in the Statement. These interim financial information have been reviewed by other auditor whose report has been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the report of the other auditor and the procedures performed by us as stated in paragraph 3 above.

   Our conclusion on the Statement is not modified in respect of this matter.

7. The unaudited consolidated financial results includes the interim financial information of two subsidiaries which have not been reviewed by their auditors, whose interim financial information reflect total revenue of ₹ Nil, total loss after tax of ₹ 1.78 million and total comprehensive loss of ₹ 1.78 million for the quarter ended June 30, 2026, as considered in the Statement. According to the information and explanations given to us by the Management, this interim financial information is not material to the Group.

   Our conclusion on the Statement is not modified in respect of our reliance on this interim financial information certified by the Management.

For **Deloitte Haskins & Sells**
Chartered Accountants
(Firm's Registration No. 008082S)

Monisha Parikh
Partner
Membership No. 047840
UDIN: 26047840AVXSXI6758

Place: Bengaluru
Date: August 10, 2026

GLAND PHARMA LIMITED
Corporate Identity Number: L24239TG1978PLC002276
Registered Office: Sy. No. 143 - 148, 150 and 151, Near Gandi Maisamma 'X' Roads, D.P. Pally, Dundigal
Dundigal - Gandi Maisamma (M), Medchal-Malkajgiri District, Hyderabad 500 043, Telangana, India
Tel: +91 84556 99999; Website: www.glandpharma.com; E-mail: investors@glandpharma.com

Statement of Unaudited Consolidated Financial Results for the quarter ended June 30, 2026

(₹ in million)

Particulars	Quarter ended			Year ended
	30-Jun-26	31-Mar-26	30-Jun-25	31-Mar-26
	Unaudited	Unaudited	Unaudited	Audited
1. Income				
Revenue from operations	18,002.71	17,427.90	15,056.22	64,306.50
Other income	612.28	1,114.66	575.27	3,163.28
Total income	**18,614.99**	**18,542.56**	**15,631.49**	**67,469.78**
2. Expenses				
Cost of materials consumed	5,882.01	5,940.70	5,573.62	22,397.49
Purchase of stock-in-trade	19.45	22.78	8.81	66.04
Changes in inventories of finished goods, stock-in-trade and work-in-progress	341.84	(50.17)	(371.08)	(34.23)
Power and fuel	558.77	530.18	456.56	2,028.52
Employee benefits expense	4,439.98	4,115.74	4,080.38	16,288.39
Depreciation and amortisation expense	1,112.58	1,086.60	1,010.52	4,236.67
Finance costs	43.61	100.30	114.96	332.79
Other expenses	1,866.99	1,738.47	1,630.31	7,264.85
Total expenses	**14,265.23**	**13,484.60**	**12,504.08**	**52,580.52**
3. Profit before exceptional item and tax (1-2)	**4,349.76**	**5,057.96**	**3,127.41**	**14,889.26**
4. Exceptional item (refer note 3)	-	-	-	243.46
5. Profit before tax (3-4)	**4,349.76**	**5,057.96**	**3,127.41**	**14,645.80**
6. Tax expense				
Current tax	1,267.62	1,439.60	1,010.51	4,578.14
Deferred tax	(74.75)	(48.50)	(47.36)	(215.95)
Taxes of earlier years	(12.70)	0.11	9.44	10.45
Total tax expense	**1,180.17**	**1,391.21**	**972.59**	**4,372.64**
7. Profit for the quarter/year (5-6)	**3,169.59**	**3,666.75**	**2,154.82**	**10,273.16**
Attributable to:				
- Owners of the Company	**3,169.59**	**3,666.75**	**2,154.82**	**10,273.16**
- Non-controlling interests	-	-	-	-
8. Other comprehensive income				
Items that will not be reclassified subsequently to profit or loss:				
Remeasurement of defined benefit plans	(25.13)	(66.25)	13.34	(135.62)
Deferred tax impact on remeasurement of defined benefit plans	6.35	31.47	(2.46)	34.45
Items that will be reclassified subsequently to profit or loss:				
Exchange differences on translation of foreign operations	285.95	(974.36)	(1,875.77)	(4,208.70)
Total other comprehensive (income)/loss, net of tax	**267.17**	**(1,009.14)**	**(1,864.89)**	**(4,309.87)**
9. Total comprehensive income (7-8)	**2,902.42**	**4,675.89**	**4,019.71**	**14,583.03**
Attributable to:				
- Owners of the Company	**2,902.42**	**4,675.89**	**4,019.71**	**14,583.03**
- Non-controlling interests	-	-	-	-
10. Paid up equity share capital (Face value of ₹1/- each)	**164.96**	**164.76**	**164.76**	**164.76**
11. Other equity				**103,414.74**
12. Earnings per equity share (Face value of ₹1/- each):				
(Not annualised for the quarter)				
Basic (₹)	19.23	22.26	13.08	62.35
Diluted (₹)	19.22	22.23	13.08	62.28

DELOITTE HASKINS & SELLS CHARTERED ACCOUNTANTS

GLAND PHARMA LIMITED HYDERABAD, INDIA GLAND

Notes:

1. In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing requirements"), this Statement of Unaudited Consolidated Financial Results for the quarter ended June 30, 2026 ("Consolidated Financial Results") of Gland Pharma Limited (the "Holding Company" or the "Company") and its subsidiaries, (the Holding Company and its subsidiaries together referred to as the "Group") has been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on August 10, 2026. The statutory auditors have carried out a limited review on the Unaudited Consolidated Financial Results and issued an unmodified report thereon.

2. The Unaudited Consolidated Financial Results of the Group have been prepared in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013, as amended and read with relevant rules thereunder and in terms of the Listing

3. The Government of India consolidated 29 existing labour legislations into a unified framework comprising four Labour Codes, viz. The Code on Wages, 2019, The Industrial Relations Code, 2020, The Code on Social Security, 2020, and The Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as the "New Labour Codes"). These New Labour Codes became effective from November 21, 2025.

   The Company assessed the implications of the New Labour Codes and made an additional provision of ₹ 243.46 million for gratuity and leave liability towards employee benefits during the quarter ended December 31, 2025, and year ended March 31, 2026. Considering the regulatory driven and non - recurring nature of the impact, the Company presented the incremental impact as an "Exceptional item".

4. The figures of the quarter ended March 31, 2026 are the balancing figures between audited figures in respect of the full previous financial year and the published unaudited year-to-date figures up to the end of the third quarter of the previous financial year, which were subjected to a limited review.

5. The Group is engaged in the manufacture and sale of "Pharmaceuticals" which constitutes a single reportable business segment as per Ind AS 108- 'Operating Segments'.

6. The previous periods/year numbers have been regrouped/rearranged wherever necessary to conform with the current period presentation.

7. The above Unaudited Consolidated Financial Results of the Group are available on the Company's website www.glandpharma.com and also on the website of BSE Limited (www.bseindia.com) and National Stock Exchange of India Limited (www.nseindia.com), where the equity shares of the Company are listed.

DELOITTE HASKINS & SELLS CHARTERED ACCOUNTANTS

GLAND PHARMA LIMITED GLAND HYDERABAD, INDIA

For and on behalf of the Board
Gland Pharma Limited

S. Srinivas

Srinivas Sadu
Executive Chairman
DIN No. 06900659

Hyderabad
August 10, 2026

Deloitte Haskins & Sells

Chartered Accountants
Meenakshi Pride Rock-Tower III
[Block-M], 8th & 9th Floors,
Survey No. 23, Gachibowli,
Serilingampally Municipality
Ranga Reddy District,
Hyderabad-500032
Telangana, India

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF GLAND PHARMA LIMITED

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **Gland Pharma Limited** ("the Company"), for the quarter ended June 30, 2026 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **Deloitte Haskins and Sells**
Chartered Accountants
(Firm's Registration No.008072S)

Monisha Parikh
Partner
Membership No. 047840
UDIN: 26047840AXSGBU1078

Place: Bengaluru
Date: August 10, 2026

GLAND PHARMA LIMITED
Corporate Identity Number: L24239TG1978PLC002276
Registered Office: Sy. No. 143 - 148, 150 and 151, Near Gandi Maisamma 'X' Roads, D.P. Pally, Dundigal
Dundigal - Gandi Maisamma (M), Medchal-Malkajgiri District, Hyderabad 500 043, Telangana, India
Tel: +91 84556 99999; Website: www.glandpharma.com; E-mail: investors@glandpharma.com

Statement of Unaudited Standalone Financial Results for the quarter ended June 30, 2026

(₹ in million)

Particulars	Quarter ended			Year ended
	30-Jun-26	31-Mar-26	30-Jun-25	31-Mar-26
	Unaudited	Unaudited	Unaudited	Audited
1. **Income**				
Revenue from operations	12,866.40	12,615.92	10,388.35	45,520.92
Other income	588.21	1,063.57	547.41	3,038.97
Total income	**13,454.61**	**13,679.49**	**10,935.76**	**48,559.89**
2. **Expenses**				
Cost of materials consumed	4,694.46	4,609.57	4,398.24	17,952.19
Purchase of stock-in-trade	19.45	22.78	8.81	66.04
Changes in inventories of finished goods, stock-in-trade and work-in-progress	358.56	215.54	(142.18)	(66.65)
Power and fuel	336.32	298.24	301.21	1,223.83
Employee benefits expense	1,439.09	1,339.56	1,284.36	5,288.18
Depreciation and amortisation expense	439.53	431.10	437.68	1,762.43
Finance costs	6.91	61.65	74.35	180.73
Other expenses	1,283.39	1,053.06	949.46	4,426.57
Total expenses	**8,577.71**	**8,031.50**	**7,311.93**	**30,833.32**
3. **Profit before exceptional item and tax (1-2)**	**4,876.90**	**5,647.99**	**3,623.83**	**17,726.57**
4. Exceptional item (refer note 3)	-	-	-	243.46
5. **Profit before tax (3-4)**	**4,876.90**	**5,647.99**	**3,623.83**	**17,483.11**
6. **Tax expense**				
Current tax	1,264.62	1,432.14	932.71	4,525.19
Deferred tax	(18.93)	11.34	(1.46)	(38.29)
Taxes of earlier years	(12.70)	-	-	0.70
Total tax expense	**1,232.99**	**1,443.48**	**931.25**	**4,487.60**
7. **Profit for the quarter/year (5-6)**	**3,643.91**	**4,204.51**	**2,692.58**	**12,995.51**
8. **Other comprehensive income**				
Items that will not be reclassified subsequently to profit or loss:				
Remeasurement of defined benefit plans	(21.63)	(74.69)	9.77	(86.51)
Deferred tax impact on remeasurement of defined benefit plans	5.44	18.79	(2.46)	21.77
Total other comprehensive (income)/loss, net of tax	**(16.19)**	**(55.90)**	**7.31**	**(64.74)**
9. **Total comprehensive income (7-8)**	**3,660.10**	**4,260.41**	**2,685.27**	**13,060.25**
10. **Paid up equity share capital (Face value of ₹1/- each)**	**164.96**	**164.76**	**164.76**	**164.76**
11. Other equity				**107,935.57**
12. **Earnings per equity share (Face value of ₹1/- each):**				
(Not annualised for the quarter)				
Basic (₹)	22.11	25.52	16.34	78.88
Diluted (₹)	22.10	25.49	16.34	78.78

DELOITTE HASKINS & SELLS CHARTERED ACCOUNTANTS

GLAND PHARMA LIMITED HYDERABAD, INDIA GLAND

Notes:

1. In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing requirements"), this Statement of Unaudited Standalone Financial Results for the quarter ended June 30, 2026 ("Standalone Financial Results") of the Company has been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on August 10, 2026. The statutory auditors have carried out a limited review on the Unaudited Standalone Financial Results and issued an unmodified report thereon.

2. The Unaudited Standalone Financial Results of the Company have been prepared in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013, as amended and read with relevant rules thereunder and in terms of the Listing requirements.

3. The Government of India consolidated 29 existing labour legislations into a unified framework comprising four Labour Codes, viz. The Code on Wages, 2019, The Industrial Relations Code, 2020, The Code on Social Security, 2020, and The Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as the "New Labour Codes"). These New Labour Codes became effective from November 21, 2025.

   The Company assessed the implications of the New Labour Codes and made an additional provision of ₹ 243.46 million for gratuity and leave liability towards employee benefits during the quarter ended December 31, 2025, and year ended March 31, 2026. Considering the regulatory driven and non - recurring nature of the impact, the Company presented the incremental impact as an "Exceptional item".

4. The figures of the quarter ended March 31, 2026 are the balancing figures between audited figures in respect of the full previous financial year and the published unaudited year-to-date figures up to the end of the third quarter of the previous financial year, which were subjected to a limited review.

5. The Company is engaged in the manufacture and sale of "Pharmaceuticals" which constitutes a single reportable business segment as per Ind AS 108- 'Operating Segments'.

6. The previous periods/year numbers have been regrouped/rearranged wherever necessary to conform with the current period presentation.

7. The above Unaudited Standalone Financial Results of the Company are available on the Company's website www.glandpharma.com and also on the website of BSE Limited (www.bseindia.com) and National Stock Exchange of India Limited (www.nseindia.com), where the equity shares of the Company are listed.

DELOITTE HASKINS & SELLS CHARTERED ACCOUNTANTS

GLAND PHARMA LIMITED HYDERABAD, INDIA GLAND

For and on behalf of the Board
Gland Pharma Limited

S. Srinivas

Srinivas Sadu
Executive Chairman
DIN No. 06900659

Hyderabad
August 10, 2026

Press Release

Gland Pharma Reports Yet Another Quarter with Record Revenues

Revenue Growth @ 20% Y-o-Y | PAT Growth @ 47% Y-o-Y

Hyderabad, August 10th, 2026: Gland Pharma Limited (BSE: 543245 | NSE: GLAND), an injectable-focused pharmaceutical company, announced its financial results for the first quarter and year ended June 30th, 2026.

Commenting on the results, **Mr. Srinivas Sadu, Executive Chairman of Gland Pharma**, stated, ***"Our strong start to FY27 reflects the successful execution of our CDMO strategy and the resilience of our B2B business model. Growth was driven by recent product launches from CDMO portfolio and strong customer demand for our diversified product mix. We continue to strengthen our growth platform through a robust CDMO pipeline including investments in differentiated technologies and capacity expansions, which position us well for sustainable long-term growth."***

Consolidated Financial Performance

₹ Mn

Particulars	Q1 FY27	Q1 FY26	YoY	Q4 FY26	QoQ
Revenue from operations	18,003	15,056	20%	17,428	3%
Gross Profit(1)	11,759	9,845	19%	11,515	2%
Gross Profit margin (%)	65%	65%		66%	
EBITDA(2)	4,930	3,678	34%	5,130	-4%
EBITDA margin (%)(3)	27%	24%		29%	
Adj. EBITDA(4)	5,102	3,737	37%	5,244	-3%
Adj. EBITDA margin (%)	28%	25%		30%	
PBT	4,350	3,127	39%	5,058	-14%
PBT margin (%)	24%	21%		29%	
PAT	3,170	2,155	47%	3,667	-14%
PAT margin (%)	18%	14%		21%	

1. Gross Profit = Revenue from Operations – Materials consumed; 2. EBITDA = Profit before tax plus finance expense plus depreciation and amortization expense excluding other income and forex losses. 3. EBITDA margin = EBITDA / Revenue from operations; 4.Adj. EBITDA = EBITDA plus Employee stock option compensation expenses.

Financial Highlights:

- Quarterly revenue increased by 20% year-on-year.
- Quarterly R&D investments stood at ₹ 772 million.
- Quarterly adj. EBITDA increased by 37% year-on-year.
- Quarterly adj. EBITDA margin stood at 28%.
- Quarterly PAT increased by 47% year-on-year.
- Quarterly PAT margin increased by ~330 bps year-on-year.
- CDMO business contributed 50% of revenues and grew by 20% year-on-year in Q1FY27.
- B2B* business contributed 50% of revenues and grew by 19% year-on-year in Q1FY27.

** Including B2C Revenue INR 152 Mn in Q1FY27, INR 147 Mn in Q1FY26, INR 147 Mn in Q4FY26.*

Business-wise Performance

₹ Mn

Business	Q1 FY27	Q1 FY26	YoY	Q4 FY26	QoQ
CDMO	8,915	7,411	20%	8,059	11%
B2B*	9,088	7,645	19%	9,369	-3%
Total	**18,003**	**15,056**	**20%**	**17,428**	**3%**

** Including B2C Revenue INR 152 Mn in Q1FY27, INR 147 Mn in Q1FY26, INR 147 Mn in Q4FY26.*

Market-wise Performance

₹ Mn

Markets	Q1 FY27	Q1 FY26	YoY	Q4 FY26	QoQ
USA	9,810	7,443	32%	9,807	0%
Europe	3,954	3,302	20%	3,814	4%
Canada, Australia and New Zealand *(Other Core Markets)*	534	739	-28%	588	-9%
India	666	594	12%	670	-1%
Rest of the world	3,039	2,978	2%	2,549	19%
TOTAL	**18,003**	**15,056**	**20%**	**17,428**	**3%**

Business Highlights:

- **R&D Expenses:** Total R&D expenses were ₹772 million in Q1 FY27, representing 4% of consolidated revenue. The R&D expenditure was mainly focused on complex product development and the number of filings.

- **New Launches:** The company launched 4 molecules in the USA this quarter, including Multi-Vitamin and Leucovorin calcium.

- **Filings and Approvals:** Three ANDAs were filed, and seven were approved in Q1 FY27, contributing to a cumulative total of 389 ANDA filings in the U.S. (342 approved, 47 pending).

- **In-house Complex Pipeline:** Six products have already been launched, and three more are in line for approval. Complex injectables are expected to remain a central pillar of long-term growth, with more products being added to the pipeline.

- **Co-development Partnerships:** Fifteen products are in co-development (seven 505(b)(2) and eight ANDAs), with commercialization anticipated to begin in FY28.

- **Ready-to-Use (RTU) Bags:** Filed 21 Ready-to-Use infusion bag products and received approval for 18 so far. An additional 11 are currently under development. The total RTU bag portfolio addresses a market opportunity of approximately $644 million in the US.

- **CDMO partnership with A Global Pharmaceutical Company:** Once all products are commercialized, the annualized revenue potential is expected to be approximately USD 90–100 million. Technology transfer activities are planned for completion within two years, with revenues expected to commence from calendar year 2029.

- **Strategic collaboration with Neuland Laboratories**: Long-term strategic collaboration for the manufacturing of sterile APIs for microparticle depot products.

- **In-licensing agreement with a China-based development company** for the development, manufacturing and commercialization of a niche liposomal product for the U.S. and European markets.

Earnings Call Details

The Company will conduct an Earnings call at 6.30 PM (IST) on August 10th, 2026, to discuss the business performance and answer participants' questions. To participate in this conference call, please dial the numbers provided below ten minutes before the scheduled start time.

Universal Access	**+91 22 6280 1516 / +91 22 7115 8875**
Diamond pass link	Click ***here*** to register
National Toll-Free	1 800 120 1221
International Toll-Free Number	USA – 18667462133 UK – 08081011573 Singapore – 8001012045 Hong Kong – 800964448

About Gland Pharma Limited (BSE: 543245, NSE: GLAND)

Gland Pharma was established in 1978 in Hyderabad and has grown over the years from a contract manufacturer of small-volume liquid parenteral products to become one of the largest and fastest-growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. It operates primarily under a Contract Development & Manufacturing Operations (CDMO), Business-to-Business (B2B) model and has an excellent track record in the development, manufacturing, and marketing of sterile injectables. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions, and also enjoys the distinction of having pioneered Heparin technology in India. For more information, log on to: www.glandpharma.com

Investor Contacts

Sampath Kumar Pallerlamudi
Company Secretary and Compliance Officer

Shriniwas P. Dange
Investor Relations
investors@glandpharma.com

GLAND PHARMA

Investor Presentation

Q1 FY27

10th August 2026

Safe Harbour Statement

The Presentation is to provide the general background information about the Company's activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any investor should subscribe / purchase the company shares.

This presentation may include certain "forward looking statements". These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others general economic and business conditions in India and any other country, ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global pharmaceuticals industries, increasing competition, changes in political conditions in India or any other country and changes in the foreign exchange control regulations in India. Neither the company, nor its directors and any of the affiliates or employee have any obligation to update or otherwise revise any forward-looking statements. The readers may use their own judgment and are advised to make their own calculations before deciding on any matter based on the information given herein.

No part of this presentation may be reproduced, quoted or circulated without prior written approval from Gland Pharma Limited.

Financial Highlights

Consolidated P&L

₹ Mn

Particulars	Q1 FY27	Q1 FY26	YoY	Q4 FY26	QoQ
Revenue from operations	**18,003**	**15,056**	20%	**17,428**	3%
Other Income	612	575	6%	1,115	-45%
Total Income	**18,615**	**15,631**	19%	**18,543**	0%
Gross Profit[1]	**11,759**	**9,845**	19%	**11,515**	2%
Gross Profit margin (%)	*65%*	*65%*		*66%*	
EBITDA[2]	**4,930**	**3,678**	34%	**5,130**	-4%
EBITDA margin(%)[3]	*27%*	*24%*		*29%*	
Adj.EBITDA[4]	**5,102**	**3,737**	37%	**5,244**	-3%
Adj. EBITDA margin(%)	*28%*	*25%*		*30%*	
PBT	**4,350**	**3,127**	39%	**5,058**	-14%
PBT margin(%)	*24%*	*21%*		*29%*	
PAT	**3,170**	**2,155**	47%	**3,667**	-14%
PAT margin(%)	*18%*	*14%*		*21%*	

1. Gross Profit = Revenue from Operations – Materials consumed; 2. EBITDA = Profit before tax plus finance expense plus depreciation and amortization expense, excluding other income and forex losses. 3. EBITDA margin = EBITDA / Revenue from operations;4. Adj. EBITDA = EBITDA plus Employee stock option compensation expenses.

Consolidated Financial Highlights (1/3)

Revenue from Operations
(₹ Mn)



Gross Profit[1] / Gross Profit Margin[2]
(₹ Mn / %)



Adj. EBITDA[3] / Adj. EBITDA Margin[4] / PAT / PAT Margin
(₹ Mn / %)



R&D Expenditure
(₹ Mn / % of Consolidated revenue)



1. Gross Profit = Revenue from Operations – Materials consumed 2. Gross Profit Margin = Gross profit /Revenue from operations 3. Adj. EBITDA = EBITDA plus Employee stock option compensation expenses.. 4. Adj. EBITDA margin = Adj. EBITDA / Revenue from operations.

Consolidated Financial Highlights (2/3)









1. Net Worth refers to sum of equity share capital and other equity. 2. Return on Capital Employed (ROCE) = EBIT/ Average Capital Employed for the period. Capital Employed represents Total Assets – Current Liabilities; 3. Return on Net Worth (RONW) = Profit for the period / Average Net Worth for the period. Net Worth represents sum of equity share capital and other equity. 4. Asset Turnover is calculated as Revenue from operations for the period divided by average total assets for the period; 5. Fixed Asset Turnover is calculated as Revenue from operations for the period divided by average total fixed assets for the period (Property, plant and equipment + Right-of-use assets + Capital work in progress)

Consolidated Financial Highlights (3/3)

Cash and Bank Balances / Net Cash[1]
(₹ Mn)



. * Excluding non-callable deposits of INR 3,960 million.

Cash Flow from Operations
(₹ Mn)



Net Working Capital[2]
(₹ Mn)



Cash Conversion Cycle (CCC)[3][4]
(# of Days)



1. Net Cash refers to Cash and Cash equivalents less total borrowings(including current maturities). 2. Net Working Capital refers to Current assets (excluding cash and bank balances) less Current liabilities. 3. COGS mean cost of goods sold includes cost of materials consumed, purchases of traded goods, change in inventories of finished goods, traded goods and work-in-progress and manufacturing overheads; 4. Receivable days calculated as average trade receivables for the period divided by revenue from operations * over 90/365 days (as applicable), Inventory days calculated as average inventory for the period divided by COGS* over 90/365 days (as applicable), & Payable days calculated as average trade payable for the period divided by COGS* over 90/365 days (as applicable). CCC is calculated as Receivable days + Inventory days - Payable days.

Business Update

Business-wise Revenue Break-up

₹ Mn

Business	Q1 FY27	Q1 FY26	YoY	Q4 FY26	QoQ
CDMO	8,915	7,411	20%	8,059	11%
B2B*	9,088	7,645	19%	9,369	-3%
Total	**18,003**	**15,056**	**20%**	**17,428**	**3%**

Revenue Distribution



Business Update

- CDMO growth supported by recent product launches.
- B2B growth supported by increased demand from existing customers and higher volume.

* Including B2C Revenue INR 152 Mn in Q1FY27, INR 147 Mn in Q1FY26, INR 147 Mn in Q4FY26.

Business Updates

- **R&D Expenses:** Total R&D expenses were ₹772 million in Q1 FY27, representing 4% of consolidated revenue. The R&D expenditure was mainly focused on complex product development and the number of filings.
- **New Launches:** The company launched 4 molecules in the USA this quarter, including Multi-Vitamin and Leucovorin calcium.
- **Filings and Approvals:** Three ANDAs were filed, and seven were approved in Q1 FY27, contributing to a cumulative total of 389 ANDA filings in the U.S. (342 approved, 47 pending).
- **In-house Complex Pipeline:** Six products have already been launched, and three more are in line for approval. Complex injectables are expected to remain a central pillar of long-term growth, with more products being added to the pipeline.
- **Co-development Partnerships:** Fifteen products are in co-development (seven 505(b)(2) and eight ANDAs), with commercialization anticipated to begin in FY28.
- **Ready-to-Use (RTU) Bags:** Filed 21 Ready-to-Use infusion bag products and received approval for 18 so far. An additional 11 are currently under development. The total RTU bag portfolio addresses a market opportunity of approximately $644 million in the US.
- **CDMO partnership with A Global Pharmaceutical Company:** Once all products are commercialized, the annualized revenue potential is expected to be approximately USD 90–100 million. Technology transfer activities are planned for completion within two years, with revenues expected to commence from calendar year 2029.
- **Strategic collaboration with Neuland Laboratories**: Long-term strategic collaboration for the manufacturing of sterile APIs for microparticle depot products.
- **In-licensing agreement with a China-based development company** for the development, manufacturing and commercialization of a niche liposomal product for the U.S. and European markets.

Geographical Revenue

US Market

₹ *Mn*

Revenue Contribution



CDMO



B2B



US Filings Update

	Q1FY27	Cumulative
ANDAs[1]		
- Filed	3	389
- Approved	7	342

US Contribution



Business Update

- **CDMO:** Growth driven by recent product launches – Dalbavancin and Multi-Vitamin;
- **B2B:** Volume expansion in existing products, including Enoxaparin, Vancomycin, Chlorothiazide and Heparin.
- **New Product Launches:** Launched 4 molecules.

Note: 1. ANDA count includes technology transfer ANDAs.

Europe Market

₹ Mn

Revenue Contribution



CDMO



B2B



Europe Contribution



Business Update

- Volume expansion in existing products, including Daptomycin and Cenexi CDMO products.
- Recent product launch – Dalbavancin.

Other Core Markets (Canada, Australia and New Zealand)

₹ Mn

Revenue Contribution



CDMO



B2B



Other Core Markets Contribution



Business Update

- Volume decline in the existing products led to revenue degrowth.

Rest of the World

₹ Mn

Revenue Contribution



CDMO



B2B



RoW Contribution



Business Update

- Growth seen across some of the key products, including Heparin, Huminsulin and Rocuronium Bromide.

India

₹ *Mn*

Revenue Contribution



CDMO



B2B*



India Contribution



Business Update

- Growth seen in CDMO for certain products, including Huminsulin.
- Decline in B2B due to lower sales of Enoxaparin.

* Including B2C Revenue INR 152 Mn in Q1FY27, INR 147 Mn in Q1FY26, INR 147 Mn in Q4FY26.

GLAND PHARMA

Thank You

Investor Relations

Sampath Kumar Pallerlamudi
Company Secretary & Compliance Officer

Shriniwas P. Dange
Investor Relations
investors@glandpharma.com

Corporate Office

Gland Pharma Limited
Plot No. 11 & 84, TSIIC Phase: IV
Pashamylaram (V), Patancheru (M),
Sangareddy District
Hyderabad 502307, Telangana, India

BSE 543245 NSE GLAND Bloomberg GLAND:IN